Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06769490
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
44 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Acute Myeloid Leukemia
NOT_YET_RECRUITING
NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
116 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Ovarian Cancer


Ovarian Carcinoma, Recurrent


Ovarian Cancer Metastatic Recurrent


Ovarian Cancer (OvCa)
RECRUITING
NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
146 Enrollment(s)
148 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Salivary Gland Carcinoma


Recurrent Salivary Gland Carcinoma


Stage III Major Salivary Gland Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Unresectable Salivary Gland Carcinoma
COMPLETED
NCT04744831
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
122 Enrollment(s)
63 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Colorectal Cancer
RECRUITING
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
792 Enrollment(s)
45 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07333937
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
35 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Brest Cancer
RECRUITING
NCT07015697
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
76 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Recurrent or Metastatic Solid Tumors
RECRUITING
NCT06731478
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
726 Enrollment(s)
249 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer


Gastroesophageal Junction Cancer